{"entity":{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","aka":[],"tldr":"The clinician half of the partnership that turned a liposome chemistry idea into Doxil, and the person who did the trials that showed it behaved differently in patients from free doxorubicin.","summary":"Alberto Gabizon worked with Yechezkel Barenholz at the Hebrew University on pegylated liposomal doxorubicin and then took it into patients, establishing the pharmacokinetics that distinguish it from free doxorubicin: a long circulation half-life, accumulation in tumour tissue, and a toxicity profile in which hand-foot syndrome and mucositis replace alopecia and cardiac damage. The product was approved by the FDA in 1995 and remains standard in relapsed ovarian cancer, used as a single agent or with carboplatin, trabectedin or bevacizumab, and as the comparator arm in modern trials including MIRASOL. He continues to work at Shaare Zedek Medical Center on nanomedicine pharmacology and combination strategies.","asOf":"2026-09-25","links":[{"label":"Shaare Zedek Medical Center","url":"https://www.szmc.org.il/eng/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gabizon%20A%5BAuthor%5D%20liposomal%20doxorubicin"},{"label":"Europe PMC author and affiliation search","url":"https://europepmc.org/search?query=AUTH%3A%22Gabizon%20A%22%20AND%20liposomal"}],"tags":["clinician-scientist","drug-delivery"],"related":[],"cancers":["ovarian","kaposi-sarcoma"],"sections":["drug-discovery","chemotherapy"],"technologies":[],"targets":[],"drugs":["pegylated-liposomal-doxorubicin","doxorubicin"],"companies":[],"institutions":["shaare-zedek","hebrew-university-of-jerusalem"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Oncologist, Shaare Zedek Medical Center; professor, Hebrew University-Hadassah Medical School","institutionId":"shaare-zedek","specialisms":["Liposomal drug delivery","Pharmacokinetics of nanomedicines","Ovarian and breast cancer","Early-phase trials"],"profiles":[{"label":"Shaare Zedek Medical Center","url":"https://www.szmc.org.il/eng/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gabizon%20A%5BAuthor%5D%20liposomal%20doxorubicin"},{"label":"Europe PMC author and affiliation search","url":"https://europepmc.org/search?query=AUTH%3A%22Gabizon%20A%22%20AND%20liposomal"}],"papers":[{"title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","journal":"Cancer Research","year":1994,"url":"https://pubmed.ncbi.nlm.nih.gov/8313389/","note":"PMID 8313389. Plasma clearance 0.1 litres per hour for the liposomal form against 45 for free doxorubicin, and a volume of distribution of 4 litres against 254."},{"title":"Doxil, the first FDA-approved nano-drug: lessons learned","journal":"Journal of Controlled Release","year":2012,"doi":"10.1016/j.jconrel.2012.03.020","note":"Barenholz Y; the retrospective covering the joint programme"}]},"route":"/people/alberto-gabizon/","neighbours":{"cancer":[{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"}],"institution":[{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/"},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/"}]}}